St John's Research Institute working with Max Planck Institute
Even as tuberculosis (TB) cuts a swathe through the country, efforts are being made to curtail the spread of the disease and offer succour to sufferers.
As part of the overall campaign, the St John’s Research Institute in the City has announced its decision to work with world-renowned scientist-immunologist, Prof Stefan H E Kaufmann, Director of the Department of Immunology at the Max Planck Institute for Infection Biology in Berlin, in fine-tuning a BCG vaccine that Kaufmann has developed against the disease. Dr . John Kenneth will head the clinical research work from Bangalore.
Speaking to Deccan Herald, Kaufmann said St John’s Institute will be active in the clinical part of vaccine development, while the Max Planck Institute will concentrate on basic research. “The institute in Bangalore will screen patients and obtain data of their health status and interact with us on the basis of that data. Together, we will combine their practice with our theoretical research to strengthen the vaccine that has been developed.” Kenneth told this newspaper that St John’s would be doing translational research — where doctors contribute to basic research by working with patients. “We are the only translational research institute in the country and we would be proud to contribute to the vaccine against TB.”
The St John’s Institute will also assist the Max Planck Institute by identifying biomarkers in the blood of patients to discover whether a patient is diseased or not. Identifying bio-markers is part of clinical activity. Once the markers are identified, the data is passed on to basic researchers who may re-examine their theories.